Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis

Jean Paul Ortonne; Mark Lebwohl; Christopher Em Griffiths; Kirk Barber; Eileen Murray; Marc Bourcier; Wayne Gulliver; Richard Langley; Lynn Guenther; Kim Papp; Jerry Tan; Yves Poulin; Michel Heenen; Julien Lambert; Michel De La Brassine; Knud Kragballe; Frederik Grönhöj-Larsen; Philippe Humbert; Gerard Guillet; Pierre Thomas; Jean Luc Schmutz; Louis Dubertret; Gerard Lorette; Wolfram Sterry; Peter Altmeyer; Gottfried Wozel; Enno Christophers; Gustav Mahrle; Uwe Frithjof Haustein; Gerd Plewig; Thomas Luger; Mario Leicha; Maximiliano Aragües; Adolpho Aliaga; J. D. Bos; Peter Van De Kerkhof; Arnold Oranje; James Ferguson; Lesley Rhodes; Jonathan Barker; Dow Stough; Regina Hamlin; Stacy Smith; Margaret Drehobl; Nick Lowe; Robert Brown; Christopher Nelson; James Aton; Mark Ling; Kenneth Gordon; Donald Belsito; Daniel Stewart; Craig Leonardi; Michael Heffernan; Thomas Casale; David Hassman; Diane Baker; Janet Roberts; Harold Farber; Ellen Frankel; Keith Loven; Hans Sander; Peter Hino; John Gonzalez; Thomas Nigra

Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis

Jean Paul Ortonne, Mark Lebwohl, Christopher Em Griffiths, Kirk Barber, Eileen Murray, Marc Bourcier, Wayne Gulliver, Richard Langley, Lynn Guenther, Kim Papp, Jerry Tan, Yves Poulin, Michel Heenen, Julien Lambert, Michel De La Brassine, Knud Kragballe, Frederik Grönhöj-Larsen, Philippe Humbert, Gerard Guillet, Pierre ThomasJean Luc Schmutz, Louis Dubertret, Gerard Lorette, Wolfram Sterry, Peter Altmeyer, Gottfried Wozel, Enno Christophers, Gustav Mahrle, Uwe Frithjof Haustein, Gerd Plewig, Thomas Luger, Mario Leicha, Maximiliano Aragües, Adolpho Aliaga, J. D. Bos, Peter Van De Kerkhof, Arnold Oranje, James Ferguson, Lesley Rhodes, Jonathan Barker, Dow Stough, Regina Hamlin, Stacy Smith, Margaret Drehobl, Nick Lowe, Robert Brown, Christopher Nelson, James Aton, Mark Ling, Kenneth Gordon, Donald Belsito, Daniel Stewart, Craig Leonardi, Michael Heffernan, Thomas Casale, David Hassman, Diane Baker, Janet Roberts, Harold Farber, Ellen Frankel, Keith Loven, Hans Sander, Peter Hino, John Gonzalez, Thomas Nigra

Research output: Contribution to journal › Article › peer-review

Abstract

This international, double-blind study examined the effects of alefacept on circulating lymphocytes in 507 patients with chronic plaque psoriasis, and determined whether these effects were related to clinical improvement. Patients were randomized to intramuscular placebo, alefacept 10 mg, or alefacept 15 mg once weekly for 12 weeks followed by 12 weeks of observation. Alefacept dose-dependently reduced CD4+ and CD8+ memory T cells, while sparing the naïve population. The greatest reductions in disease activity occurred in patients with the largest decreases in memory T cells. For example, a ≥ 50% reduction from baseline Psoriasis Area Severity Index at any time during treatment or follow-up was observed in 66% of patients who had the greatest reductions in CD4+ memory T cells versus in 40% of patients who had the smallest reductions in this T-cell subset. These results provide further support for the deleterious roles of CD4+ and CD8+ memory T-cell subpopulations in psoriasis pathogenesis.

Original language	English
Pages (from-to)	117-123
Number of pages	6
Journal	European Journal of Dermatology
Volume	13
Issue number	2
Publication status	Published - Mar 2003

Keywords

Alefacept
Amevive®
Efficacy
Pharmacodynamics
Psoriasis
T lymphocytes

Cite this

Ortonne, J. P., Lebwohl, M., Em Griffiths, C., Barber, K., Murray, E., Bourcier, M., Gulliver, W., Langley, R., Guenther, L., Papp, K., Tan, J., Poulin, Y., Heenen, M., Lambert, J., De La Brassine, M., Kragballe, K., Grönhöj-Larsen, F., Humbert, P., Guillet, G., ... Nigra, T. (2003). Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. European Journal of Dermatology, 13(2), 117-123.

@article{b367466c0b6c468595c87eb5605e1423,

title = "Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis",

abstract = "This international, double-blind study examined the effects of alefacept on circulating lymphocytes in 507 patients with chronic plaque psoriasis, and determined whether these effects were related to clinical improvement. Patients were randomized to intramuscular placebo, alefacept 10 mg, or alefacept 15 mg once weekly for 12 weeks followed by 12 weeks of observation. Alefacept dose-dependently reduced CD4+ and CD8+ memory T cells, while sparing the na{\"i}ve population. The greatest reductions in disease activity occurred in patients with the largest decreases in memory T cells. For example, a ≥ 50% reduction from baseline Psoriasis Area Severity Index at any time during treatment or follow-up was observed in 66% of patients who had the greatest reductions in CD4+ memory T cells versus in 40% of patients who had the smallest reductions in this T-cell subset. These results provide further support for the deleterious roles of CD4+ and CD8+ memory T-cell subpopulations in psoriasis pathogenesis.",

keywords = "Alefacept, Amevive{\textregistered}, Efficacy, Pharmacodynamics, Psoriasis, T lymphocytes",

author = "Ortonne, {Jean Paul} and Mark Lebwohl and {Em Griffiths}, Christopher and Kirk Barber and Eileen Murray and Marc Bourcier and Wayne Gulliver and Richard Langley and Lynn Guenther and Kim Papp and Jerry Tan and Yves Poulin and Michel Heenen and Julien Lambert and {De La Brassine}, Michel and Knud Kragballe and Frederik Gr{\"o}nh{\"o}j-Larsen and Philippe Humbert and Gerard Guillet and Pierre Thomas and Schmutz, {Jean Luc} and Louis Dubertret and Gerard Lorette and Wolfram Sterry and Peter Altmeyer and Gottfried Wozel and Enno Christophers and Gustav Mahrle and Haustein, {Uwe Frithjof} and Gerd Plewig and Thomas Luger and Mario Leicha and Maximiliano Arag{\"u}es and Adolpho Aliaga and Bos, {J. D.} and {Van De Kerkhof}, Peter and Arnold Oranje and James Ferguson and Lesley Rhodes and Jonathan Barker and Dow Stough and Regina Hamlin and Stacy Smith and Margaret Drehobl and Nick Lowe and Robert Brown and Christopher Nelson and James Aton and Mark Ling and Kenneth Gordon and Donald Belsito and Daniel Stewart and Craig Leonardi and Michael Heffernan and Thomas Casale and David Hassman and Diane Baker and Janet Roberts and Harold Farber and Ellen Frankel and Keith Loven and Hans Sander and Peter Hino and John Gonzalez and Thomas Nigra",

year = "2003",

month = mar,

language = "English",

volume = "13",

pages = "117--123",

journal = "European Journal of Dermatology",

issn = "1952-4013",

publisher = "John Libbey",

number = "2",

}

Ortonne, JP, Lebwohl, M, Em Griffiths, C, Barber, K, Murray, E, Bourcier, M, Gulliver, W, Langley, R, Guenther, L, Papp, K, Tan, J, Poulin, Y, Heenen, M, Lambert, J, De La Brassine, M, Kragballe, K, Grönhöj-Larsen, F, Humbert, P, Guillet, G, Thomas, P, Schmutz, JL, Dubertret, L, Lorette, G, Sterry, W, Altmeyer, P, Wozel, G, Christophers, E, Mahrle, G, Haustein, UF, Plewig, G, Luger, T, Leicha, M, Aragües, M, Aliaga, A, Bos, JD, Van De Kerkhof, P, Oranje, A, Ferguson, J, Rhodes, L, Barker, J, Stough, D, Hamlin, R, Smith, S, Drehobl, M, Lowe, N, Brown, R, Nelson, C, Aton, J, Ling, M, Gordon, K, Belsito, D, Stewart, D, Leonardi, C, Heffernan, M, Casale, T, Hassman, D, Baker, D, Roberts, J, Farber, H, Frankel, E, Loven, K, Sander, H, Hino, P, Gonzalez, J & Nigra, T 2003, 'Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis', European Journal of Dermatology, vol. 13, no. 2, pp. 117-123.

TY - JOUR

T1 - Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis

AU - Ortonne, Jean Paul

AU - Lebwohl, Mark

AU - Em Griffiths, Christopher

AU - Barber, Kirk

AU - Murray, Eileen

AU - Bourcier, Marc

AU - Gulliver, Wayne

AU - Langley, Richard

AU - Guenther, Lynn

AU - Papp, Kim

AU - Tan, Jerry

AU - Poulin, Yves

AU - Heenen, Michel

AU - Lambert, Julien

AU - De La Brassine, Michel

AU - Kragballe, Knud

AU - Grönhöj-Larsen, Frederik

AU - Humbert, Philippe

AU - Guillet, Gerard

AU - Thomas, Pierre

AU - Schmutz, Jean Luc

AU - Dubertret, Louis

AU - Lorette, Gerard

AU - Sterry, Wolfram

AU - Altmeyer, Peter

AU - Wozel, Gottfried

AU - Christophers, Enno

AU - Mahrle, Gustav

AU - Haustein, Uwe Frithjof

AU - Plewig, Gerd

AU - Luger, Thomas

AU - Leicha, Mario

AU - Aragües, Maximiliano

AU - Aliaga, Adolpho

AU - Bos, J. D.

AU - Van De Kerkhof, Peter

AU - Oranje, Arnold

AU - Ferguson, James

AU - Rhodes, Lesley

AU - Barker, Jonathan

AU - Stough, Dow

AU - Hamlin, Regina

AU - Smith, Stacy

AU - Drehobl, Margaret

AU - Lowe, Nick

AU - Brown, Robert

AU - Nelson, Christopher

AU - Aton, James

AU - Ling, Mark

AU - Gordon, Kenneth

AU - Belsito, Donald

AU - Stewart, Daniel

AU - Leonardi, Craig

AU - Heffernan, Michael

AU - Casale, Thomas

AU - Hassman, David

AU - Baker, Diane

AU - Roberts, Janet

AU - Farber, Harold

AU - Frankel, Ellen

AU - Loven, Keith

AU - Sander, Hans

AU - Hino, Peter

AU - Gonzalez, John

AU - Nigra, Thomas

PY - 2003/3

Y1 - 2003/3

N2 - This international, double-blind study examined the effects of alefacept on circulating lymphocytes in 507 patients with chronic plaque psoriasis, and determined whether these effects were related to clinical improvement. Patients were randomized to intramuscular placebo, alefacept 10 mg, or alefacept 15 mg once weekly for 12 weeks followed by 12 weeks of observation. Alefacept dose-dependently reduced CD4+ and CD8+ memory T cells, while sparing the naïve population. The greatest reductions in disease activity occurred in patients with the largest decreases in memory T cells. For example, a ≥ 50% reduction from baseline Psoriasis Area Severity Index at any time during treatment or follow-up was observed in 66% of patients who had the greatest reductions in CD4+ memory T cells versus in 40% of patients who had the smallest reductions in this T-cell subset. These results provide further support for the deleterious roles of CD4+ and CD8+ memory T-cell subpopulations in psoriasis pathogenesis.

AB - This international, double-blind study examined the effects of alefacept on circulating lymphocytes in 507 patients with chronic plaque psoriasis, and determined whether these effects were related to clinical improvement. Patients were randomized to intramuscular placebo, alefacept 10 mg, or alefacept 15 mg once weekly for 12 weeks followed by 12 weeks of observation. Alefacept dose-dependently reduced CD4+ and CD8+ memory T cells, while sparing the naïve population. The greatest reductions in disease activity occurred in patients with the largest decreases in memory T cells. For example, a ≥ 50% reduction from baseline Psoriasis Area Severity Index at any time during treatment or follow-up was observed in 66% of patients who had the greatest reductions in CD4+ memory T cells versus in 40% of patients who had the smallest reductions in this T-cell subset. These results provide further support for the deleterious roles of CD4+ and CD8+ memory T-cell subpopulations in psoriasis pathogenesis.

KW - Alefacept

KW - Amevive®

KW - Efficacy

KW - Pharmacodynamics

KW - Psoriasis

KW - T lymphocytes

M3 - Article

SN - 1952-4013

VL - 13

SP - 117

EP - 123

JO - European Journal of Dermatology

JF - European Journal of Dermatology

IS - 2

ER -

Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis

Abstract

Keywords

Fingerprint

Cite this